Aisling Capital’s Loxo Oncology, Inc LOXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-2,038,920
| Closed | -$286M | – | 7 |
|
|
2018
Q4 | $286M | Hold |
2,038,920
| – | – | 80.87% | 1 |
|
|
2018
Q3 | $348M | Sell |
2,038,920
-1,400,000
| -41% | -$235M | 75.27% | 1 |
|
|
2018
Q2 | $597M | Hold |
3,438,920
| – | – | 78.3% | 1 |
|
|
2018
Q1 | $397M | Hold |
3,438,920
| – | – | 70.71% | 1 |
|
|
2017
Q4 | $289M | Sell |
3,438,920
-750,000
| -18% | -$62.5M | 57.19% | 1 |
|
|
2017
Q3 | $386M | Hold |
4,188,920
| – | – | 63.39% | 1 |
|
|
2017
Q2 | $336M | Hold |
4,188,920
| – | – | 57.53% | 1 |
|
|
2017
Q1 | $176M | Buy |
4,188,920
+160,000
| +4% | +$6.59M | 32.09% | 1 |
|
|
2016
Q4 | $129M | Hold |
4,028,920
| – | – | 30.09% | 1 |
|
|
2016
Q3 | $105M | Hold |
4,028,920
| – | – | 21.73% | 1 |
|
|
2016
Q2 | $93.4M | Buy |
4,028,920
+232,558
| +6% | +$5.79M | 22.05% | 1 |
|
|
2016
Q1 | $104M | Hold |
3,796,362
| – | – | 20.78% | 1 |
|
|
2015
Q4 | $108M | Buy |
3,796,362
+343,869
| +10% | +$9.23M | 18.63% | 1 |
|
|
2015
Q3 | $60.4M | Hold |
3,452,493
| – | – | 10.61% | 4 |
|
|
2015
Q2 | $62.2M | Hold |
3,452,493
| – | – | 9.27% | 4 |
|
|
2015
Q1 | $43M | Hold |
3,452,493
| – | – | 5.63% | 4 |
|
|
2014
Q4 | $40.6M | Hold |
3,452,493
| – | – | 6.15% | 8 |
|
|
2014
Q3 | $45.3M | Buy |
+3,452,493
| New | +$44.8M | 8.79% | 4 |
|
Other funds holding LOXO
Aisling Capital's LOXO Position: Q1 2019 in Review
Aisling Capital sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 2,038,920 shares — an estimated $286M sold.
Aisling Capital first reported a position in LOXO in Q3 2014 and held it in 18 quarters. The position peaked at $597M in Q2 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.
- Aisling Capital reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
- Aisling Capital sold 2,038,920 Loxo Oncology, Inc shares in Q1 2019, an estimated $286M.
- Aisling Capital first reported a position in Loxo Oncology, Inc in Q3 2014 and held it in 18 quarters.
- Aisling Capital's Loxo Oncology, Inc position peaked at $597M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.
Based on Aisling Capital's 13F filing for Q1 2019, filed 7 May 2019.